Opendata, web and dolomites

HypoSkin SIGNED

Unique breakthrough ex vivo human skin model to predict efficacy and toxicity of subcutaneous drugs

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HypoSkin project word cloud

Explore the words cloud of the HypoSkin project. It provides you a very rough idea of what is the project "HypoSkin" about.

110    sabatier    local    sharp    ready    national    times    first    reduces    instrument    framework    88    2011    hyposkin    view    biological    faster    trials    risks    complete    standardized    plans    security    vivo    parenteral    clinical    experiment    customers    decrease    global    predict    2024    drug    1b    absence    effect    route    secure    injection    model    700k    time    reliably    subcutaneous       industrialise    permits    confirmed    university    company    market    pharmaceuticals    health    regulatory    spin    improves    sales    containing    replace    disruptive    qualify    vitro    34    animal    tissue    cheaper    device    inadequate    sharpen    home    care    payed    accurate    provides    patient    deepen    companies    scientific    quality    reference    worldwide    founded    center    turnover    toulouse    biopsies    innovative    limits    issue    2017    ex    life    attrition    french    feasibility    world    genoskin    skin    human    models    cagr    off    leads    living    pilot    fat    alternative    money    innovation    medical    save    paul    causing    jobs    administration    sme    kit   

Project "HypoSkin" data sheet

The following table provides information about the project.

Coordinator
GENOSKIN SAS 

Organization address
address: CENTRE PIERRE POTIER, 1 PLACE PIERRE POTIER
city: TOULOUSE
postcode: 31100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.genoskin.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GENOSKIN SAS FR (TOULOUSE) coordinator 50˙000.00

Map

 Project objective

Subcutaneous injection drug market is highly increasing (CAGR of 7%) and is view as a viable alternative route for parenteral drug administration because it enables at-home injection, improves quality of life and reduces health care costs. However, the absence of accurate biological model to predict the effect of drug injection in the subcutaneous tissue limits their development. That issue leads to 88% of drug attrition causing a loss of more than €1B per developed drug and a sharp decrease of patient security during clinical trials.

HypoSkin is the first and unique in vitro standardized and ready-to-use testing kit containing living ex vivo human skin biopsies with subcutaneous fat, allowing pharmaceuticals to highly reliably predict local human’s response to the injection of a drug or a medical device. This disruptive innovation permits Hyposkin’s customers to save time and money (10 times faster and 5 times cheaper than animal experiment, confirmed in the on-going payed pilot test) as well as secure the development of their products before clinical trials. HypoSkin will become worldwide reference method to replace inadequate animal testing currently used today.

HypoSkin model is developed by Genoskin an innovative French company, founded in 2011 as a spin-off of the French National Center for Scientific Research and the Paul Sabatier University in Toulouse. Genoskin provides other human-skin alternative models to pharmaceuticals companies all over the world leading to sales of €700K in 2017.

The SME Instrument project will allow the company to improve, qualify and industrialise HypoSkin. To accomplish this goal Genoskin will complete a feasibility study to further analyse risks and cost of scale-up, the European regulatory framework and will deepen and sharpen the global subcutaneous injection market. Genoskin plans to lead the European and global alternative method market with an estimated turnover of € 34 M by 2024, and 110 new European and worldwide jobs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HYPOSKIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HYPOSKIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More